514 related articles for article (PubMed ID: 11444087)
1. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women.
Trémollieres FA; Pouilles JM; Ribot C
Osteoporos Int; 2001; 12(5):385-90. PubMed ID: 11444087
[TBL] [Abstract][Full Text] [Related]
2. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.
Bagger YZ; Tankó LB; Alexandersen P; Hansen HB; Møllgaard A; Ravn P; Qvist P; Kanis JA; Christiansen C
Bone; 2004 Apr; 34(4):728-35. PubMed ID: 15050905
[TBL] [Abstract][Full Text] [Related]
3. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
4. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer.
Saarto T; Vehmanen L; Elomaa I; Välimäki M; Mäkelä P; Blomqvist C
Br J Cancer; 2001 Apr; 84(8):1047-51. PubMed ID: 11308252
[TBL] [Abstract][Full Text] [Related]
5. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
Brodowska A
Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
[TBL] [Abstract][Full Text] [Related]
6. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial.
Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Honkanen R; Saarikoski S
Osteoporos Int; 2000; 11(3):211-8. PubMed ID: 10824236
[TBL] [Abstract][Full Text] [Related]
7. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of continuous combined HRT on bone turnover and lipid metabolism in postmenopausal women.
Hart DM; Farish E; Fletcher CD; Barnes JF; Hart H; Nolan D; Spowart K
Osteoporos Int; 1998; 8(4):326-32. PubMed ID: 10024902
[TBL] [Abstract][Full Text] [Related]
9. Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study.
Sornay-Rendu E; Garnero P; Munoz F; Duboeuf F; Delmas PD
Bone; 2003 Jul; 33(1):159-66. PubMed ID: 12919711
[TBL] [Abstract][Full Text] [Related]
10. Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen?
Tuppurainen MT; Komulainen M; Kröger H; Honkanen R; Jurvelin J; Puntila E; Heikkinen AM; Alhava E; Saarikoski S
Osteoporos Int; 1998; 8(1):32-8. PubMed ID: 9692075
[TBL] [Abstract][Full Text] [Related]
11. Risk factors associated with peri- and postmenopausal bone loss: does HRT prevent weight loss-related bone loss?
Sirola J; Kröger H; Honkanen R; Sandini L; Tuppurainen M; Jurvelin JS; Saarikoski S
Osteoporos Int; 2003 Jan; 14(1):27-33. PubMed ID: 12577182
[TBL] [Abstract][Full Text] [Related]
12. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up.
Tuppurainen M; Härmä K; Komulainen M; Kiviniemi V; Kröger H; Honkanen R; Alhava E; Jurvelin J; Saarikoski S
Maturitas; 2010 Aug; 66(4):423-30. PubMed ID: 20547017
[TBL] [Abstract][Full Text] [Related]
13. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
Wimalawansa SJ
Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
[TBL] [Abstract][Full Text] [Related]
14. [Absence of antiosteopenic effect of hormone replacement therapy in postmenopausal women].
Ortiz Núñez DA; Mengchún López G; Hernández Marín I; Mendoza R; Ayala Ruíz AR
Ginecol Obstet Mex; 2004 Jul; 72():349-55. PubMed ID: 15469174
[TBL] [Abstract][Full Text] [Related]
15. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial.
Arrenbrecht S; Boermans AJ
Osteoporos Int; 2002; 13(2):176-83. PubMed ID: 11908492
[TBL] [Abstract][Full Text] [Related]
16. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone.
Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P
J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347
[TBL] [Abstract][Full Text] [Related]
17. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial.
Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Alhava E; Honkanen R; Jurvelin J; Saarikoski S
J Clin Endocrinol Metab; 1999 Feb; 84(2):546-52. PubMed ID: 10022414
[TBL] [Abstract][Full Text] [Related]
18. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.
Barrett-Connor E; Wehren LE; Siris ES; Miller P; Chen YT; Abbott TA; Berger ML; Santora AC; Sherwood LM
Menopause; 2003; 10(5):412-9. PubMed ID: 14501602
[TBL] [Abstract][Full Text] [Related]
19. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study.
Greendale GA; Espeland M; Slone S; Marcus R; Barrett-Connor E;
Arch Intern Med; 2002 Mar; 162(6):665-72. PubMed ID: 11911720
[TBL] [Abstract][Full Text] [Related]
20. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
Gambacciani M; Cappagli B; Ciaponi M; Pepe A; Vacca F; Genazzani AR
Maturitas; 2008 Jan; 59(1):2-6. PubMed ID: 18063490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
